obesity overweight
Conditions
Interventions
Subjects will be exposed to mild-cold using a dedicated cooling device
(Blanketrol® III, Cincinnati Sub-Zero (CSZ) Products, Inc). The system consists
of a heater, a compressor, a circulating pump a
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: objective 1 (MR protocol optimization): - Age between 18-45 years - BMI 18-25 kg/m2 objective 2: - Age between 18-35 years - BMI 18-25 kg/m2 - White Caucasian men and women
Exclusion criteria
Exclusion criteria: Diagnosed medical conditions known to affect lipid/glucose metabolism, BAT activity or cardiac function Medication known to affect lipid/glucose metabolism, BAT activity or cardiac function (e.g. beta blockers, thyroid supplements, antidepressants) Inability to lay still for longer than 30 minutes Smoking Recent excessive weight change Contraindications to MR scanning Any significant chronic disease resulting from the screening sample (objective 2 only)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameters for both objectives are dynamic MR outcomes in response to mild-cold in the hypothalamus, BAT and skeletal muscles. | — |
Secondary
| Measure | Time frame |
|---|---|
| Only applicable to objective 2: - Dynamic MR outcomes in the hypothalamus, BAT and skeletal muscles during thermoneutrality (32°C) - Cold-induced changes in serum markers for sympathetic output (norepinephrine, epinephrine) - Cold-induced changes is serum markers for glucose metabolism (glucose, insulin, cortisol) - Cold-induced changes in serum markers for lipid metabolism (triglycerides (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), high density lipoprotein cholesterol (LDL-C), free fatty acids) - Cold-induced changes in BAT markers(e.g. microRNA92a, FGF21, peroxidized lipids, lysoPC(16:0), lysoPC(16:1) and PC(32:1)) - Cold-induced changes in lipoproteins | — |
Countries
Netherlands
Outcome results
None listed